NGM Biopharmaceuticals Future Growth

How is NGM Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

4.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:NGM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	19	-172	-55	-47	4
12/31/2024	17	-148	-67	-60	6
12/31/2023	27	-142	-87	-90	5
9/30/2022	58	-153	-134	-132	N/A
6/30/2022	69	-135	-115	-114	N/A
3/31/2022	77	-125	-89	-87	N/A
12/31/2021	78	-120	-75	-73	N/A
9/30/2021	77	-121	-77	-75	N/A
6/30/2021	82	-122	-93	-91	N/A
3/31/2021	85	-111	-88	-87	N/A
12/31/2020	87	-102	-85	-83	N/A
9/30/2020	99	-90	-81	-78	N/A
6/30/2020	97	-72	-62	-60	N/A
3/31/2020	102	-54	-50	-48	N/A
12/31/2019	104	-43	-45	-41	N/A
9/30/2019	120	-13	-22	-20	N/A
6/30/2019	119	-9	-22	-19	N/A
3/31/2019	116	-5	-22	-15	N/A
12/31/2018	109	0	-13	-8	N/A
9/30/2018	81	-17	-24	-18	N/A
6/30/2018	80	-12	-22	-15	N/A
3/31/2018	77	-13	-21	-16	N/A
12/31/2017	77	-14	-24	-17	N/A
12/31/2016	86	-7	-24	1	N/A

Earnings vs Savings Rate: NGM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NGM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NGM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NGM's revenue (15.3% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: NGM's revenue (15.3% per year) is forecast to grow slower than 20% per year.

Future ROE: Insufficient data to determine if NGM's Return on Equity is forecast to be high in 3 years time